Metanoic Health Clinical Trials
DEFEAT-COVID Study CASE REPORT FORM Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19)
This study aims to test the patients that avoiding exposure to COVID-19.
Following a screening visit, participants will be invited to 3 module visits over a 14 days period, and will undergo a range of measurements and tests.
Title: A Randomised Controlled Multicentre Study evaluating changes in Cardiovascular Risk Factors in Smokers with type 2 Diabetes Mellitus after switching from Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE 2.0 Study
This study aims to test the hypothesis that avoiding exposure to cigarette smoke toxicants may translate to measurable improvement in cardiovascular risk factors and functional parameters when type 2 diabetes mellitus (T2DM) patients who smoke switch to using C-F NDS compared with T2DM patients who continue to smoke conventional tobacco products.
Participants will be randomized (1:2 ratio) to either continue to smoke commercially manufactured cigarettes (Study Arm A) or combustion-free nicotine delivery systems (C-F NDS) (Study Arm B).
Before randomization, all smokers will be reminded of the risks associated with smoking and will be offered a free smoking cessation program according to standard local guidelines and depending on the local availability of antismoking services. Those who decline the invitation will be eligible for recruitment into the RCT.
Following a screening visit, participants will be invited to five study visits over a 24 month period, and will undergo a range of measurements and blood tests.
Title: Noctura 400 treatment for Diabetic Retinopathy
The purpose of this study is to assess the clinical and cost-effectiveness of Noctura 400 light masks as an adjuvant therapy for centre-involving Diabetic Macular Oedema (DMO).
Funder & Sponsor: PolyPhotonix Ltd
Click here for visit candle trial site
Title: Six Lead Atrial Fibrillation Study (SL-AF)
The study is designed to test the use of a novel technology called the RhythmPadGP for the diagnosis of Atrial Fibrillation.
Funder & Sponsor: Cardiocity Ltd.
Title: Incidence of significant mitral regurgitation in patients presenting with acute heart failure
The purpose of this research is to study the incidence of significant MR (grade 3 and above) in patients with symptoms of breathlessness and palpitations requiring hospital admission.
Funder: Abbott
Sponsor: Metanoic Health Ltd.
Click here for visit Heart Failure site
Title: WHAT ARE THE HAND HYGIENE PRACTICES AND DRIVERS FOR HEALTHCARE PROFESSIONALS IN HOSPITAL WARD SETTINGS?
The purpose of this research is to further understand the glove use and behaviour of healthcare workers in acute and community hospital settings, and examine whether there are any differences between staff groups.
Funder & Sponsor: Industrial Microbiological Services Ltd.
Click here for visit Gloves Study site
Title: Detection of Heart Rhythm and Blood Pressure with RhythmPadBP
The purpose of this study is to evaluate the effectiveness of RhythmPadBP, in accurately detecting heart rhythm and recording blood pressure simultaneously.
Funder & Sponsor: Cardiocity Ltd.
Title: A single-centre, open study to investigate the performance of the intravenous MicroEye® blood sampling device in combination with the ContinuMon® glucose measurement system in ICU patients
The purpose of this trial is to evaluate the performance of the MicroEye® device for intravenous microdialysis and the ContinuMon® device for measuring glucose in ICU patients.
Funder & Sponsor: Probe Scientific Ltd.
Click here for visit Microeye and Continumon Trial site
GENESIS Study: A 12-month randomized, double-blind, controlled, international multicentre trial comparing changes in Cigarette consumption after switching to high or low nicotine strength E-cigarettes In smokers with Schizophrenia spectrum disorders.
Although smoking it is rewarding for you, it is bad for your general health. It is also particularly harmful for people living with some mental health conditions. For example, smoking is associated with more depressive symptoms, increased stress, enhanced psychotic symptoms and poor response to antipsychotic treatments.
By stopping smoking you could experience an overall improvement of psychiatric symptoms with less anxiety and depression with an overall improvement of your psychological quality of life. Moreover, you might be able to reduce the level of medications you’re taking.
Considering what has been said so far, quitting smoking will help manage your mental health condition better and contrast the development and the progression of smoking related diseases. No matter how much or how long you have smoked, quitting always helps your health in many ways.
Quitting may not be easy, however. It has been suggested that for people not intending or not able to quit smoking, it is easier to substitute conventional tobacco cigarettes with combustion-free nicotine delivery systems (known as e-cigarettes) to achieve potential health gains.
GENESIS Study is investigating whether switching to these combustion-free nicotine delivery alternatives reduces your need to smoke tobacco cigarettes.
In particular, the results of the study may help us to understand if switching to e-cigarette can accomplish high quit and reduction rates that persist long-term in people with mental health problems.
Click here for visit Genesis Study Trial site
XLEAR eCRF Targeting Clinical Efficacy of Nitric Oxide Nasal Spray (XLEAR) for the Treatment of COVID-19 Infection. XLEAR COVID-19 study aims to collect data obtained through examination, discussion and review of hospital notes.
Following a screening visit, participants will be invited to 3 module visits over a 14 days period, and will undergo a range of measurements and tests.
This study is exploring sensitive measurements of early signs of tobacco harm. It is well established that tobacco smoking causes damage to your lungs but there is no easy diagnostic test to quantify. The results of this study may help us to identify sensitive markers using CT scans and respiratory tests. These measurements will be linked with blood, urine and breath biomarkers. We hope, in future, simple blood, breath or urine test can be used instead of CT scans and respiratory tests to quantify lung damage caused by tobacco smoking.